Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Acura, Pfizer Advance OXECTA Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Acura, Pfizer Advance OXECTA Partnership

To expand oxycodone commercialization

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer is expanding commercialization of OXECTA (oxycodone HCl) Tablets CII to health care providers in 4Q13. Acura Pharmaceuticals, Inc. has exclusively licensed its AVERSION Technology to Pfizer in the U.S., Canada and Mexico for use in OXECTA and receives royalties ranging from 5% to 25% on sales.
 
“We are pleased Pfizer is advancing the commercialization plan for OXECTA,” said Bob Jones, president and chief executive officer of Acura Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters